Sorcero MedTech launch enables single AI platform for drug and device analytics, spanning the patient journey

Sorcero has acquired real-world data platform Axiom Health in a strategic move to unify analytics across the pharmaceutical and medical device sectors. The acquisition sees the launch of Sorcero MedTech, integrating Axiom’s data lake with the Sorcero Intelligence Platform to create a single AI-powered system for cross-vertical insights.

The move positions Sorcero as the first to offer unified commercial and medical analytics for both drug and device organisations. With the medical technology market now valued at $595 billion, according to Medical Product Outsourcing, the deal broadens Sorcero’s reach and relevance across a rapidly evolving life sciences ecosystem.

“The integration of pharmaceutical and medical device data unlocks critical insights that have been siloed for too long,” said Dipanwita Das, CEO of Sorcero. “Teams can now gain a complete picture of the patient journey, from device to drug, helping guide product development and commercial decision-making.”

The enhanced platform will offer:

• Cross-sector analytics between pharma, medtech, and stakeholders

• Real-time AI insights across product development and market strategy

• Detailed visibility into treatment pathways and patient experience

• Stakeholder micro-targeting based on usage and impact data

• Deeper unmet needs identification to inform clinical and commercial priorities

A. Krishna, Founder and President of Axiom Health, joins Sorcero as SVP of MedTech. “We can now deliver unified device and drug insights from a single source,” he said. “This creates new opportunities for personalised engagement with physicians and key opinion leaders (KOLs), grounded in real-world usage patterns and scientific sentiment.”

The transaction was backed by First Trust Capital Partners, LLC, alongside Axiom’s existing investors.

“This combination sits at the intersection of AI innovation and healthcare delivery,” said Jon Phillips, managing director at First Trust. “It addresses a real gap in the market and opens new growth opportunities in life sciences AI.”